<listing id="vjp15"></listing><menuitem id="vjp15"></menuitem><var id="vjp15"></var><cite id="vjp15"></cite>
<var id="vjp15"></var><cite id="vjp15"><video id="vjp15"><menuitem id="vjp15"></menuitem></video></cite>
<cite id="vjp15"></cite>
<var id="vjp15"><strike id="vjp15"><listing id="vjp15"></listing></strike></var>
<var id="vjp15"><strike id="vjp15"><listing id="vjp15"></listing></strike></var>
<menuitem id="vjp15"><strike id="vjp15"></strike></menuitem>
<cite id="vjp15"></cite>
<var id="vjp15"><strike id="vjp15"></strike></var>
<var id="vjp15"></var>
<var id="vjp15"></var>
<var id="vjp15"><video id="vjp15"><thead id="vjp15"></thead></video></var>
<menuitem id="vjp15"></menuitem><cite id="vjp15"><video id="vjp15"></video></cite>
<var id="vjp15"></var><cite id="vjp15"><video id="vjp15"><thead id="vjp15"></thead></video></cite>
<var id="vjp15"></var>
<var id="vjp15"></var>
<menuitem id="vjp15"><span id="vjp15"><thead id="vjp15"></thead></span></menuitem>
<cite id="vjp15"><video id="vjp15"></video></cite>
<menuitem id="vjp15"></menuitem>

13-烷氧代-3,15-二氧代赤霉酸酯及其制備方法

文檔序號:3523079閱讀:297來源:國知局
專利名稱:13-烷氧代-3,15-二氧代赤霉酸酯及其制備方法
技術領域
本發明涉及醫藥衛生和化學領域的藥用化合物,具體是一種13-烷氧代-3, 15-二氧代赤霉酸酯類物質及其制備方法。
背景技術
惡性胂瘤是嚴重威脅人類健康的一類疾病,化學療法是目前控制和治療惡性 腫瘤的重要手段。化學療法的核心是高活性,高選擇性、無毒或低毒副作用的 抗癌化合物的發現和應用。目前臨床應用的化療藥物不少都有使患者惡心、嘔 吐、白細胞下降、骨髓抑制等毒副作用,影響了患者身體健康和生活質量,因 而極大地限制了化療藥物的臨床應用。因此,尋找治療指數高的抗肺瘤新化合 物成為新藥研究的一項重要課題。
赤霉素是一類廣泛存在于植物和微生物體內、具有植物生長促進或植物生 長抑制生物活性的四環二萜類化合物,以商業化發酵生產的赤霉素,如GA3、 GA4、 GA7為原料進行結構改造,以期發現具有更好植物生長促進或植物生長抑 制活性以及其它諸如抗菌、抗癌等新活性的赤霉素及其衍生物有著重要的應用 價值。
在本發明前期的研究中,本申請的發明人以赤霉酸GA3為原料合成得到的3 位和15位同時被氧化成羰基的赤霉酸衍生物并發現這類化合物具有很強的抗癌 活性,同時對正常細胞毒性較低,已于2004年申請了專利并獲得授權,專利號 為ZL200410021939。近期我們又發現13位卣代的3, 15-二氧代赤霉酸酯具有 很好的抗肺瘤活性。在本發明中我們制備了一系列13位烷氧基化的衍生物并發 現這一類化合物具有顯著的體外對人腫瘤細胞株生長增殖的抑制活性。

發明內容
本發明提出了一種具有結構通式(A)的化合物即13-烷氧代-3, 15-二氧 代赤霉酸酯類物質,本發明并提供了該化合物的制備方法,該類化合物經抗癌 活性實驗證明,具有較強的體外抗腫瘤活性。
本發明的目的是這樣實現的
4R1 = CH;j;2-5個碳的垸基及PhCH2 R2 = H; Ar; ArCH2及卜5個碳的垸基
18
式中R1為曱基、2個碳到5個碳的烷基、芐基;R2為氫、取代的芐基及1個碳到 5個》友的烷基。
本發明制備上述化合物的方法如下以3, 13, 15-三羥基赤霉酸酯(2)為起始 原料,化合物(2)參照專利ZL200410021939中的方法制備。化合物(2)在低才及性 溶劑中低溫下加入二甲亞砜與適當比例的草酰氯或二甲亞砜與氯化亞砜形成的 氧化劑,氧化3位和15位羥基為3, 15-二羰基的同時,13位同時發生氯代反 應生成具有結構通式(1)的化合物,即13-卣代-3, 15-二氧代赤霉酸酯。
以化合物(2)制備化合物(1)的反應式如下<formula>formula see original document page 5</formula>
式中(l)和(2)的R^CH3;2-5個碳的烷基及千基, a) DMSO, C1COCOC1或DMSO,SOCl2,NEt3/CH2Cl2。
所述的低極性溶劑為苯、曱苯、二氯曱烷、三氯甲烷、正已烷、環已烷、 石油醚,用量為10-100mL溶劑/g底物;以二甲亞砜與草酰氯或二甲亞砜與氯 化亞砜在-7(TC至-4(TC下形成的化合物為氧化劑,加入侍氧化和氯代的底物 后反應5-30分鐘,再加入三乙胺進行反應5-30分鐘。
所述的化合物用量按摩爾比為底物/二甲亞砜/草酰氯或氯化亞砜/三乙 胺=1/2 ~ 50/2 ~ 6/4-100。優先采用各化合物用量按摩爾比為底物/二甲亞砜 /草酰氯/三乙胺=1/10/5/14。
13-鹵代-3, 15-二氧代赤霉酸酯(1)在甲醇、乙醇、丙醇、異丙醇、丁醇、異丁醇、戊醇、異戊醇、己醇、環己醇、節醇、對甲氧基節醇、對羥基節
醇、3, 4, 5-三甲氧基芐醇或3, 4-二甲氧基節醇等與烷氧其相對應的醇試劑中,
在脫卣素無機鹽試劑如碳酸鉀、碳酸鈉、碳酸氫鈉、碳酸銀、碳酸鋰、碳酸銫、 三氟醋酸銀、三氟磺酸銀、醋酸銀、硝酸銀等的存在下,在極性溶劑中反應得
到13-烷氧代-3, 15-二氧代赤霉酸酯(A),醇試劑用量為10 100mL溶劑/g底 物,無機鹽試劑用量為底物/無機鹽=1/1~50。極性溶劑是相應的醇、乙腈、 丙酮或者N,N-二甲基甲酰胺。反應溫度釆用室溫或60° C至相應溶劑回流溫度。 較優選的制備具有結構通式(A)的13-烷氧代-3, 15-二氧代赤霉酸酯的方 法,是將13-鹵代-3, 15-二氧代赤霉酸酯(l)在相應的醇溶劑或在乙腈或在N, N-二甲基甲酰胺溶劑中加入與烷氧基相應的醇試劑,然后加入碳酸鉀、碳酸鈉、 碳酸氫鈉、碳酸銀、碳酸鋰、碳酸銫、三氟醋酸銀、三氟磺酸銀、醋酸銀或硝 酸銀無機鹽試劑,在室溫或攝氏60度至回流溫度加熱下反應制備目標物,反應 中各化合物的用量按摩爾比為底物/醇/無機鹽=1/10 - 500/1-5。 化合物(A)的制備反應式如下,
(1) (A)
式中(1)及(A)的1^=013;2-5個碳的烷基及千基, (A)的R2 = CH3; 2-5個碳的烷基及千基及取代的節基, b)醇/無機鹽,加熱。
具有結構通式(A)的化合物與至少一種藥物上可接受的賦形劑或載體制得 的藥物組合在制備治療癌癥藥物方面的應用,可用于治療癌癥。
具體實施例方式
以下結合實施方式列舉本發明的典型化合物,但本發明并不僅限于這些實 施例或纟皮這些實施例所限制。化合物1參見CN 200810058297. 1中的方法制備。 結構通式為(A)的化合物13-烷氧代-3, 15-二氧代赤霉酸酯的通用制備方
6法如下
化合物1 ( 300毫克,0. 77毫摩爾)溶于5-15毫升的相應無水醇中,加入 碳酸銀212毫克,回流反應24個小時。薄層層析檢測反應結束后,減壓蒸干溶 劑.加入20-25毫升乙酸乙酯,用水洗2次,每次5毫升,飽和食鹽水5毫升洗 滌1次,有機相用無水硫酸鈉干燥,過濾除去干燥劑,減壓蒸出溶劑至干,得 淺黃色粉末狀固體,粗品275mg。硅膠柱層析正己烷/乙酸乙酯=5/1—2/1,純 化得白色固體化合物75-310毫克。收率20-80%。 13卩-乙酰氧基-3,15- 二氧赤霉酸甲酯 (10e"/—13p畫acetoxy-3,15-dioxo-10p-hydroxy畫20誦norgibberGlla-l,16隱dkne-7,19-d ioic acid 7-methyl ester 19,10-lactone):
'H腸麗R (300MHz, CDC13), 5 (ppm): 7.20 (1H,《《/= 9.3 Hz), 6.09 (1H,力,6.04 (1H, d, 9.3 Hz), 5.63 (1H,力,3.60 (1H,《《/= 10.8 Hz), 3.60 (3H,力,3.13 (1H,《/ = 10.8 Hz), 2.80 (1H, d, /= 10.2 Hz), 2.60 (1H,浙《/= 7.2, 12.6 Hz), 2.47-2.00 (3H, w), 2.09 (3H,力,1.95-1.79 (2H, w), 1.30 (3H, s). 13C NMR (75 MHz, CDC13) 3 (ppm): 201.29, 191.25, 172.82, 170.40, 169.85, 149.56, 146.10, 129.58, 119.18, 89.16, 81.71, 65.45, 61.45, 60.43, 52.34, 48.89, 48.19, 36.47, 33.91, 21.86, 17.84, 11.91.
13P-甲酰氧基-3, 15- 二氧赤霉酸甲酯
(e/i"13p-formyloxy-3,15-dioxo-10p-hydroxy-20國norgibberella-l,16-dkne國7,19-di oic acid 7曙methyl ester 19,10-lactone):
'H-畫R (300MHz, CDC13), S (ppm): 8.08 (1H, ", 7.20 (1H, c/, /= 9.3 Hz), 6.16 (1H, 力,6.08 (1H,《《/= 9.3 Hz), 5.69 (1H,力,3.65 (1H, c/, /= 10.5 Hz), 3.64 (3H, ", 3.17 (1H,《11.4 Hz), 2.84 (1H,《/= 10.5 Hz), 2.72-2.60 (1H, m), 2.50-2.38 (1H, m), 2.41 (1H, d, /= 11.4 Hz), 2.25 (1H,浙《/= 5.0, 12.6 Hz), 2.04-1.86 (2H, m), 1.34 (3H,力.13C NMR (75 MHz, CDC13) 5 (ppm): 200.87, 191.16, 172.76, 170.32, 159.55, 149.08, 145.92, 129.78, 119.65, 89.13, 82.53, 65.56, 61.55, 60.62, 52.46, 49.02, 48.27, 36.75, 34.21, 17.85, 11.98. 13P-甲氧基-3, 15- 二氧赤霉酸甲酯(e",—13p國methoxy-3,15畫dioxo國10p-hydroxy-20畫norgibberella-l,16國dkne-7,19隱dioi c acid 7-methyl ester 19,10國lactone):
'H-醒R (300MHz, CDC13), S (ppm): 7.19 (1H,《J= 9.3 Hz), 6.17 (1H,力,6.07 (1H 《 /= 9.3 Hz), 5.55 (1H,力,3.66 (1H,《 /= 10.5 Hz), 3.64 (3H,力,3.29 (3H, ", 2.83 (1H, t/, /= 10.5 Hz), 2.42-2.10 (5H, w), 1.92-1.62 (2H, m), 1.34 (3H,力.13C畫R (75 MHz, CDC13) 5 (ppm): 202.54, 191.26, 173.01, 170.59, 149.48, 146.08, 129.73, 119.30, 89.37, 80.89, 65.62, 61.63, 60.65, 52.44, 50.84, 49.29, 48.56, 34.67, 33.96, 17.77, 11.99. EIMS m/z (%) : 387 (M++1, 6%), 386 (M+, 18%), 358 (52), 355 (12), 342 (8), 331 (7), 313 (13), 310 (5), 299 (8), 282 (30), 281 (19), 255 (37), 237 (100), 223 (40), 217 (60), 205 (18), 196 (22), 185 (9), 175 (11), 165 (20), 153 (14), 141 (19), 128 (39), 115(50), 109(15).
13卩-乙氧基-3, 15- 二氧赤霉酸甲酯
(ew"13p畫ethoxy畫3,15國dioxo國10p國hydroxy國20-norgibberella-l,16-dkne-7,19國dioiG acid 7-methyl ester 19,10-lactone):
H-NMR (300MHz, CDC13), S (ppm): 7,20 (1H, d, /= 9.3 Hz), 6.13 (1H,力,6.06 (1H, d, 9.3 Hz), 5.54 (1H, s), 3.65 (1H, d, 10.5 Hz), 3.63 (3H,力,3.53-3.34 (2H, w), 2.81 (1H,《《/= 10.5 Hz), 2.42-2.20 (5H, w), 1.90-1.69 (2H, w), 1.32 (3H,力,1,20 (3H, f, J= 7.2 Hz). 13C畫R (75 MHz, CDC13) S (ppm): 202.69, 191.29, 173.00, 170.60, 149.98, 146.12, 129.66, 118.97, 89.37, 80.43, 65.57, 61.57, 60.62, 58.62, 52.39, 49.24, 48.55, 35.31, 34.60, 17.69, 15.85, 11.95. EIMS : 401 (M++1,
2%), 400 (M+, 11%), 372 (35), 356 (9), 345 (68), 327 (13), 313 (8), 296 (16), 269 (27), 267 (29), 251 (100), 231 (36), 223 (32), 208 (27), 196 (32), 185 (18), 178 (15), 157 (12), 149 (15), 141 (17), 128 (32), 115 (50), 109 (17).
13P-異丙氧基-3,15- 二氧赤霉酸甲酯
(ew/—13p—isoproxy-3,15-dioxo-10p誦hydroxy畫20-norgibberella-l,16畫diGne誦7,19國dioi c acid 7-methyl ester 19,10畫lactone):
^-畫R (300MHz, CDC13), S (ppm): 7,19 (1H,《《/= 9.3 Hz), 6.12 (1H,力,6.07 (1H,d, /= 9.3 Hz), 5.61 (1H,力,3.82-3.70 (1H, w), 3.65 (3H,力,3.63 (1H,《J= 10.2 Hz), 2.82 (1H,《 /= 10.2 Hz), 2.44 (1H, 4 /= 10.8 Hz), 2.41-2.15 (4H, w), 1.94-1.70 (2H, m), 1.34 (3H,力,1.20 (3H, d, /= 5.7 Hz), 1.18 (3H, d, /= 5.7 Hz). 13C NMR (75 MHz, CDC13) 5 (ppm): 202.84, 191.24, 172.98, 170.61, 151.15, 146.04, 129.66, 118.90, 89.39, 80.50, 66.07, 65.58, 61.58, 60.57, 52.37, 49.33, 48.55, 36.38, 36.12, 24.99, 24.64, 17.72, 11.92. EIMS w/z (%) : 415 (M++1, 9%), 414 (M+, 35%), 386 (35), 372 (25), 370 (16), 358 (9), 344 (64), 340 (21), 327 (25), 325 (33), 312 (38), 310 (35), 299 (34), 296 (17), 269 (33), 265 (17), 251 (28), 239 (100), 223 (70), 213 (51), 211 (42), 196 (47), 189 (92), 185 (81), 171 (69), 165 (56), 157 (42), 153 (26), 141 (68), 128 (26), 115(17).
13P-丙氧基-3, 15- 二氧赤霉酸甲酯
(ew卜13p-propoxy誦3,15國dioxo—10p-hydroxy-20-norgibberdla—1,16國dkne-7,19國dioiG acid 7-methyl ester 19,10-lactone):
'H-醒R (300MHz, CDC13), 5 (ppm): 7.19 (1H, /= 9.3 Hz), 6.11 (1H,力,6.04 (1H, d, /= 9.3 Hz), 5.53 (1H,》,3.62 (3H, ", 3.62 (IH, /= 10.5 Hz), 3.52-3.22 (2H, m), 2.80 (1H, /= 10.5 Hz), 2.40-2.10 (5H, m), 1.92-1.67 (2H, w), 1.65-1.52 (2H, m), 1.31 (3H,力,0.93 (3H, /= 7.2 Hz). 13C畫R (75 MHz, CDC13) S (ppm): 202.76, 191.33, 173.02, 170.64, 150.05, 146.19, 129.61, 119.00, 89.40, 80.24, 65.55, 64.74, 61.54, 60.60, 52.39, 49.22, 48.51, 35.15, 34.61, 23.54, 17.69, 11.95, 10.79. EIMS m/z (%) : 415 (M++1, 7%), 414 (]VT, 16%), 386 (29), 370 (13), 355 (8), 341 (23), 327 (14), 325 (25), 311 (51), 310 (57), 299 (22), 283 (38), 269 (24), 265 (100), 251 (31), 241 (45), 239 (49), 223 (55), 213 (46), 211 (38), 196 (50), 185 (36), 171 (22), 165 (15), 157 (10), 141 (15), 128 (32), 115 (41).
13p- 丁氧基-3,15- 二氧赤霉酸甲酯
(e /-13p-butoxy-3,15-dioxo-10p-hydroxy-20-norgibberella-l,16-diene-7,19-dioic acid 7-methyl ester 19,10-lactone)
9'H-畫R (300MHz, CDC13), 5 (ppm): 7.19 (1H,《 /= 9.3 Hz), 6.13 (1H,力,6.06 (1H, d, J= 9.3 Hz), 5.54 (1H, ", 3.64 (3H,力,3.63 (1H, d, /= 10.2 Hz), 3.48-3.30 (2H, m): 2.81 (1H, t/,《/= 10.2 Hz), 2.41-2.18 (5H, m), 1.92-1.69 (2H, w), 1.62-1.52 (2H, w), 1,48-1.34 (2H, w), 1.24 (3H,力,0.93 (3H, f, / = 7.2 Hz). 13C畫R (75 MHz, CDC13) S (ppm): 202.75, 191.28, 172.99, 170.62, 150.18, 146.11, 129.68, 118.95, 89.39, 80.28, 65.60, 62.94, 61.61, 60.68, 52.39, 49.32, 48.61, 35.18, 34.72, 32.46, 19.52, 17.73, 14.07, 11.95. EIMS m/z (%) : 430 (M++2, 6%), 428 (M+, 18%), 402 (5), 400 (19), 384 (20), 358 (28), 355 (29), 340 (10), 325 (59), 324 (63), 311 (41), 299 (34), 285 (31), 279 (100), 267 (49), 251 (65), 239 (69), 225 (33), 223 (92), 222 (51), 213 (45), 196 (85), 185 (43), 178 (27), 171 (27), 165 (17), 158 (15), 141 (14), 128 (30), 115 (42), 97(17).
13P-異丁氧基-3, 15- 二氧赤霉酸甲酯
(ew/—13p國isobutoxy國3,15-dioxo-10p誦hydroxy-20-norgibberella畫l,16國dkne誦7,19誦dio ic acid 7-methyl ester 19,10-lactone):
!H-NMR (300MHz, CDC13), S (ppm): 7.19 (1H,《《/= 9.3 Hz), 6.12 (1H, s), 6.06 (1H, t/, 《/= 9.3 Hz), 5.54 (1H,力,3.64 (3H, ", 3.63 (1H, d, J= 10.5 Hz), 3.22-3.08 (2H, w), 2.81 (1H, /= 10.5 Hz), 2.42-2.18 (5H, m), 1.92-1.65 (3H, w), 1.33 (3H, 5), 0.94 (3H, t/, J= 6.7 Hz), 0.93 (3H, 6.7 Hz). 13C畫R (75 MHz, CDC13) S (ppm):
202.85, 191.33, 173.02, 170.67, 150.22, 146.16, 129.67, 119.03, 89.42, 80.12, 69.71, 65.60, 61.59, 60.67, 52.43, 49.32, 48.59, 35.01, 34.75, 29.07, 19.59, 17.74, 11.97.
l鄧-戊氧基-3, 15- 二氧赤霉酸甲酯
(e/i/—13p誦pentyloxy-3,15畫dioxo畫10p國hydroxy-20-norgibberdla畫l,16-dkne國7,19誦d ioic acid 7-methyl ester 19,10-lactone):
'H陽N進(300MHz, CDC13), 5 (ppm): 7.18 (1H,《/= 9.3 Hz), 6.07 (1H,力,6.01 (1H, d, J= 9.3 Hz), 5.49 (1H,力,3.58 (3H,力,3.56 (1H,《■/= 10.5 Hz), 3.42-3.23 (2H, m), 2.77 (1H,《/= 10.5 Hz), 2.38-2.11 (5H, —, 1.92-1.62 (2H, m), 1.61-1.46 (2H, w), 1.35-1.22 (4H, m), 1.27 (3H, 0.84 (3H, f, 《/ = 6.7 Hz). 13C畫R (75 MHz,CDC13) 5 (ppm): 202.63, 191.23, 172.91, 170.54, 149.98, 146.18, 129.44, 118.83, 89.32, 80.15, 65.42, 63.08, 61.42, 60.48, 52.24, 49.08, 48.37, 35.02, 34.48, 29.90, 28.36, 22.54, 17.58, 14.04, 11.82.
13P-異戊氧基-3, 15- 二氧赤霉酸甲酯
(ew/—13p—isopentyloxy畫3,15-dioxo—10p-hydroxy-20-norgibberdla—l,16-dkne—了,19-dioic acid 7-methyl ester 19,10-lactone):
'H畫畫R (300MHz, CDC13), S (ppm): 7.15 (IH, J= 9.3 Hz), 6.07 (IH,力,6.01 (1H: d, 《/= 9.3 Hz), 5.48 (IH,力,3.58 (3H,力,3.57 (1H,《《/= 10.5 Hz), 3.45-3.23 (2H, m): 2.76 (IH,《/= 10.5 Hz), 2.38-2.10 (5H, m), 1.92-1.62 (3H, m), 1.50-1.38 (2H, m), 1.27 (3H, ", 0.85 (3H,《《/= 6.7 Hz), 0.84 (3H,《J= 6.7 Hz). 13C NMR (75 MHz, CDC13) S (ppm): 202.78, 191.33, 173.04, 170.66, 150.21, 146.16, 129.68, 119.01, 89.42, 80.29, 65.60, 61.60, 61.53, 60.68, 52.43, 49.31, 48.57, 39.22, 35.05, 34.72, 25.19, 22.89, 22.77, 17.75, 11.98.
l,13p- 二甲氧基-3, 15- 二氧赤霉酸甲酯
(e/i"l,13p誦dimd:hoxy國3,15-dioxo畫10p-hydroxy畫20國iiorgibberdla—16—giig—7,19-dioi c acid 7-methyl ester 19,10-lactone):
'H-麗R (300MHz, CDC13), S (ppm): 6.16 (IH,力,5.52 (1H, s), 3.79 (IH, t/, 《/= 5.1 Hz), 3.65 (3H,》,3.61 (IH,《J= 10.5 Hz), 3.35 (3H,》,3.28 (3H,》,2.98-2.51 (4H, —,2.40-2.12 (4H, m), 1.80-1.56 (2H, m), 1.22 (3H,力.13C醒R (75 MHz, CDC13) 5 (ppm): 202.22, 198.35, 174.04, 170.78, 149.47, 118.86, 93.38, 80.94, 74.99, 64.17, 61.04, 57.82, 52.40, 52.23, 50.80, 49.03, 44.45, 39.27, 34.89, 34.35, 17.69, 10.58. EIMS w/z (%) : 419 (M++l, 5%), 418 (W, 10%), 3卯(76), 387 (19), 359 (39), 358 (30), 345 (11), 342 (22), 331 (32), 327 (11), 315 (20, 313 (27), 303 (19), 283 (49), 282 (45), 255 (86), 251 (47), 237 (56), 223 (65), 217 (45), 211 (30), 196 (51), 195 (49), 173 (24), 163 (26), 149 (31), 141 (45), 128 (57), 115 (100), 105 (31).
13P-甲酰氧基-3,15- 二氧赤霉酸芐酯
ii(eAi"13p-formyloxy-3,15-dioxo-10p勿droxy-20-norgibberella國l,16-diene誦7,19畫di oic acid 7畫benzyl ester 19,10-lactone):
'H-畫R (300MHz, CDC13), S (ppm): 7.97 (IH, ", 7.30-7.12 (5H, m), 7.13 (1H,《 / =9.3 Hz), 6.01 (IH,力,6.00 (1H,《J= 9.3 Hz), 5.57 (1H,力,4.99 (2H,》,3.60 (IH, 《10.5 Hz), 3.06 (IH,《《/= 11.4 Hz), 2.80 (1H,《《/= 10.5 Hz), 2.62-2.50 (IH, w), 2.42-2.30 (IH, m), 2.28 (IH,《 /= 11.4 Hz), 2.18 (IH,浙 /= 5.1, 12.6 Hz), 1.94-1.78 (2H, w), 1.26 (3H,力.'3C麗R (75 MHz, CDC13) S (ppm): 200.76, 191.03, 172.63, 169.60, 159.38, 148.93, 145.78, 134.86, 129.64, 128.89, 128.64, 128.54, 128.48, 119.29, 89.00, 82.33, 67.45, 65.40, 61.38, 60.48, 49.00, 48.21, 36.56, 33,99, 17.69, 11.90.
13p-甲氧基-3, 15- 二氧赤霉酸芐酯
(^iM3p-methoxy國3,15畫dioxo國10p畫hydroxy-20-norgibberella畫l,16-dkne畫7,19-dioi c acid 7-benzyl ester 19,10-lactone):
iH-NMR (300MHz, CDC13), S (ppm): 7.32-7.21 (5H, m), 7.19 (1H, J= 9.3 Hz), 6.14 (IH, 。, 6.07 (IH, /= 9.3 Hz), 5.49 (IH, ", 5.08 (IH,《 /= 12.0 Hz), 5.00 (IH, d, ■/= 12.0 Hz), 3.66 (IH, J= 10.5 Hz), 3.09 (3H,力,2.87 (1H,《《/= 10.5 Hz), 2.37-2.20 (4H, m), 1.92-1.68 (2H, m), 1.35 (3H,力.13C NMR (75 MHz, CDC13) 5 (ppm): 202.60, 191.25, 172.98, 169.94, 148.87, 146.09, 135.05, 129.72, 128.88, 128.66, 128.63, 119.32, 89.35, 81.03, 67.59, 65.59, 61.56, 60.63, 50.59, 49.30, 48.63, 35.60, 33.38, 17.67, 12.07. EIMS w/z (%) : 462 (M+, 0.5o/o), 418 (1%), 389 (2), 371 (15), 356 (6), 343 (19), 327 (4), 312 (4), 280 (6), 269 (13), 237 (5), 221 (15), 217 (7), 195 (5), 165 (11), 149 (10), 128 (7), 115 (12), 91 (100). H腿S m/z Found: 485.1561, Calcd. for C27H2607Na (M+Na)+: 485.1576.
13P -乙氧基-3, 15 - 二氧赤霉酸芐酯
(ew卜13p國ethoxy國3,15-dioxo-10p-hydroxy-20-norgibberGlla-l,16-dkiie-7,19國dioit: acid 7-benzyl ester 19,10誦lactone):
!H-畫R (300MHz, CDC13), 5 (ppm): 7.37-7.21 (5H, w), 7.19 (IH,《《/= 9.3 Hz),6.12 (1H, ", 6.07 (1H,《 /= 9.3 Hz), 5.49 (1H,力,5.08 (1H, d, 《/= 12.0 Hz), 5.00 (1H,《《/= 12.0 Hz), 3.65 (1H,《《/= 10.5 Hz), 3.32-3.08 (2H, m), 2.85 (1H,《《/ = 10.5 Hz), 2.35-2.17 (5H, w), 1.92-1.71 (2H, m), 1,35 (3H,力,1.15 (3H, f,^6.9Hz). 13C畫R (75 MHz, CDC13) S (ppm): 202.70, 191.25, 172.96, 169.93, 149.56, 146.13, 135.11, 129.66, 128.86, 128.61, 118.96, 89.36, 80.65, 67.54, 65.58, 61.54, 60.70, 58.46, 49.30, 48.67, 36.26, 34.10, 17.62, 15.82, 14.31, 12.04. EIMS (%) : 476 (M+, 1%), 448 (0.2), 432 (0.8), 421 (2), 385 (8), 357 (15), 341 (6), 324 (4), 311 (5), 283 (9), 267 (10), 255 (3), 231 (5), 221 (11), 213 (4), 195 (5), 179 (7), 149 (8), 128 (6), 115(8), 107 (5), 91 (100).
13P -異丙氧基-3, 15 - 二氧赤霉酸芐酯
(e/^一13p-isoproxy-3,15-dioxo-10p-hydroxy國20畫norgibberella國l,16國dkne棚7,19國dioi c acid 7-benzyl ester 19,10畫lactone):
'H-NMR (300MHz, CDC13), S (ppm): 7.27-7.13 (5H, w), 7.12 (1H,《J= 9.3 Hz), 6.03 (1H,力,5.99 (1H, /= 9.3 Hz), 5.49 (1H,力,5.00 (1H, /= 11.7 Hz), 4.90 (1H, d, 《/= 11.7 Hz), 3.56 (1H, 10.5 Hz), 3.33-3.23 (1H, m), 2.79 (1H, d, J =
10.5 Hz), 2.30-2.10 (5H, w), 1.81-1.63 (2H, m), 1.28 (3H,力,1.01 (3H, J= 6.3 Hz), 0.98 (3H, d, J= 6.3 Hz). 13C麗R (75 MHz, CDC13) S (ppm): 202.83, 191.27, 172.98, 169.91, 150.69, 146.18, 135.02, 129.63, 128.93, 128.58, 119.14, 89.38, 80.76, 67.56, 65.96, 65.55, 61.45, 60.56, 49.21, 48.49, 37.01, 35.76, 24.85, 24.49, 17.63, 12.06. EIMS (%) : 490 (M+, 4%), 462 (1), 399 (1), 384 (2), 375 (8), 357 (17), 329 (24), 313 (22), 311 (20), 295 (7), 285 (8), 267 (15), 239 (10), 221 (9), 213 (9), 211 (7), 185 (10), 171 (13), 165 (6), 149 (12), 128 (3), 91 (100).
13P -丙氧基-3, 15 - 二氧赤霉酸芐酯
(e/if—13p-propoxy-3,15-dioxo國10p-hydroxy國20誦norgibberGlla畫l,16-diGne國7,19-dioiG acid 7-benzyl ester 19,10畫lactone):
丄H隱畫R (300MHz, CDC13), S (ppm): 7.33-7.20 (5H, w), 7.20 (1H,《9.3 Hz), 6.12 (1H,力,6.07 (1H,《/= 9.3 Hz), 5.49 (1H, ", 5.08 (1H, /= 11.7 Hz), 4.99
13(1H,《 /= 11.7 Hz), 3.65 (1H,《/ = 10.5 Hz), 3.19-3.00 (2H, w), 2.86 (1H, O 10.5 Hz), 2.38-2.18 (5H, — , 1.92-1.73 (2H, w), 1.61-1.47 (2H, m), 1.35 (3H,力,0.89 (3H, d, J= 7.5 Hz). 13C畫R (75 MHz, CDC13) S (ppm): 202.78, 191.26, 172.96, 169.95, 149.56, 146.14, 135.05, 129.65, 128.84, 128.62, 119.08, 89.36, 80.47, 67.55, 65.56, 64.63, 61.53, 60.67, 49.27, 48.64, 36.15, 34.08, 23.51, 17.61, 12.05, 10.72. EIMS m/z (%) : 490 (M+, 1%), 463 (0.8), 446 (1), 435 (0.9), 399 (2), 373 (3), 371
(4) , 357 (8), 339 (4), 329 (5), 313 (3), 311 (11), 297 (9), 285 (4), 267 (13), 239 (4), 221 (10), 213 (5), 193 (5), 149 (3), 128 (3), 115 (4), 107 (5), 91 (100).
13P - 丁氧基-3, 15 - 二氧赤霉酸芐酯
(ew"13p-butoxy-3,15-dioxo畫10p-hydroxy-20-norgibberella-l,16國dkne-7,19-diok acid 7-benzyl ester 19,10國lactone):
'H-麗R (300MHz, CDC13), 5 (ppm): 7.37-7.18 (5H, m), 7.18 (1H, d, J= 9.3 Hz), 6.11 (1H,》,6.07 (1H,《J = 9.3 Hz), 5.48 (1H,勻,5.07 (1H, c/, /= 11.8 Hz), 4.98 (1H,《J= 11.8 Hz), 3.65 (1H, c/, /= 10,5 Hz), 3.22-3.02 (2H, w), 2.86 (1H, / = 10.5 Hz), 2.33-2.10 (6H,附),1.93-1.70 (3H, /w), 1.61-1.45 (2H, w), 1.35 (3H,力,0.90 (3H,《J= 7.3 Hz). 13C畫R (75 MHz, CDC13) S (ppm): 202.78, 191.25, 172.95, 169.95, 149.57, 146.14, 135.02, 129.63, 128.81, 128.59, 119.04, 89.35, 80.45, 67.53, 65.55, 62.71, 61.49, 60.65, 49.26, 48.61, 36.09, 34.07, 32.38, 19.41, 17.60, 14.04, 12.02. EIMS m/z (%) : 504 (M+, 0.9%), 460 (1), 449 (2), 431 (1.5), 385 (4), 360 (7), 357 (10), 339 (4), 329 (6), 311 (7), 280 (3), 267 (7), 255 (6), 239 (5), 221 (5), 195
(5) , 171 (4), 165 (3), 128 (3), 107 (5), 91 (100).
13P -異丁氧基-3, 15 - 二氧赤霉酸芐酯
13p國isobutoxy-3,15陽dioxo-10p畫hydroxy-20-norgibberGlla-l,16國dkne隱7,19—dio ic acid 7-benzyl ester 19,10畫lactone):
'H-畫R (300MHz, CDC13), 5 (ppm): 7.27-7.10 (5H, w), 7.11 (1H, /= 9.3 Hz), 6.03 (1H, ", 5.99 (1H, d, 《/= 9.3 Hz), 5.40 (1H,力,5.00 (1H,《J= 11.8 Hz), 4.90(1H,《J= 11.8 Hz), 3.57 (1H,《 /= 10.5 Hz), 2.94-2.72 (2H,附),2.78 (1H,《《/ = 10.5 Hz), 2.30-2.05 (5H, w), 1.83-1.59 (3H, w), 1.27 (3H,力,0.81 (3H,《《/= 6.5 Hz): 0.80 (3H, d, /= 6.5 Hz). 13C畫R (75固z, CDC13) S (ppm): 202.82, 191.25, 172.93, 169.95, 149.65, 146.16, 135.01, 129.60, 128.77, 128.61, 119.10, 89.36, 80.31, 69.51, 67.52, 65.54, 61.49, 60.65, 49.26, 48.62, 35.99, 34.12, 28.95, 19.55, 19.49, 17.59, 12.01.
13p -戊氧基-3, 15 - 二氧赤霉酸芐酯
(e""3p-pentyloxy-3,15-dioxo國10p-hydroxy國20-norgibberella-l,16-diene-7,19-dio ic acid 7-benzyl ester 19,10-lactone):
^-畫R (300MHz, CDC13), 5 (ppm): 7.27-7.08 (5H, w), 7.11 (1H,《J= 9.3 Hz), 6.03 (1H,力,5.98 (1H, d, / = 9.3 Hz), 5.40 (1H,力,4.99 (1H,《 /= 11.7 Hz), 4.90 (1H,《 /= 11.7 Hz), 3.57 (1H, d, 《/= 10.5 Hz), 3.14-2.96 (2H, w), 2.79 (1H,《 / = 10.5 Hz), 2.30-2.05 (6H, m), 1.83-1.61 (2H, w), 1.51-1.38 (2H, w), 1.30-1.14 (3H, w), 1.26 (3H,力,0.83 (3H,《 /= 6.3 Hz). 13C畫R (75 MHz, CDC13) 5 (ppm): 202.72, 191.22, 172.91, 169.91, 149.56, 146.15, 135.01, 129.56, 128.77, 128.56, 128.50, 118.96, 89.32, 80.44, 67.47, 65.50, 62.98, 61.46, 60.61, 49.22, 48.58, 36.09, 34.03, 29.93,28.37, 22.57, 17.56, 14.09, 11.98.
13P -異戊氧基-3, 15 - 二氧赤霉酸芐酯
(e/i/—13p—isopentyloxy國3,15國dioxo—10p-hydroxy-20-norgibberGlla—1,16國dkne—7,19-dioic add 7-benzyl ester 19,10-lactone):
'H-NMR (300MHz, CDC13), S (ppm): 7.25-7.05 (5H, w), 7.12 (1H,《《/= 9.3 Hz), 6.03 (1H,力,5.98 (IH,《《/= 9.3 Hz), 5.40 (1H,力,4.99 (1H,《J= 11.8 Hz), 4.90 (1H,《J= 11.8 Hz), 3.56 (1H,《 /= 10.5 Hz), 3.20-2.96 (2H, m), 2.79 (1H,《《/ = 10.5 Hz), 2.30-2.05 (5H, w), 1.83-1.51 (3H, w), 1.41-1.28 (2H, w), 1.26 (3H,力,0.81 (3H, J= 6.5 Hz), 0.79 (3H, / = 6.5 Hz). 13C畫R (75 MHz, CDC13) S (ppm): 202.72, 191.22, 172.91, 169.92, 149.61, 146.15, 134.97, 129.55, 128.76, 128.55,
15128.52, 118.88, 89.33, 80.40, 67.46, 65.49, 61.45, 61.24, 60.59, 49.22, 48.55, 39.16, 35.96, 34.06, 25.03, 22.77, 22.71, 17.56, 11.98.
13P -芐氧基-3, 15 - 二氧赤霉酸芐酯
(ew/一13p國benzyloxy-3,15曙dioxo-10p匪hydroxy畫20-norgibbereHa畫l,16-diGne-7,19-di oic acid 7國methyl ester 19,10-lactone):
!H-畫R (300MHz, CDC13), S (ppm): 7.41-7.25 (5H, —, 7.21 (IH, t/, 《/= 9.3 Hz), 6.21 (IH,力,6.08 (1H, d, 《/= 9.3 Hz), 5.65 (IH, ", 4.55 (IH,《 /= 11.7 Hz), 4.47 (IH, t/, J= 11.7 Hz), 3.65 (3H,力,3.64 (IH, 4 /= 10.5 Hz), 2.84 (IH,《J= 10.5 Hz), 2.56-2.36 (3H, m), 2.36-2.18 (2H, m), 1.98-1.70 (2H, w), 1.35 (3H,力.13C 畫R (75 MHz, CDC13) 5 (ppm): 202.46, 191.25, 172.96, 170.58, 149.65, 146.08, 138.31, 129.66, 128.62, 127.79, 127.26, 119.42, 89,35, 81.09, 65.56, 65.42, 61.56, 60,73, 52.44, 49.21, 48.54, 35.46, 34.82, 17.72, 11.96.
通式為A的化合物的抗癌活性實驗
按照MTT方法對K562 (人白血病細胞林)等六種肺瘤細胞林的半數抑制濃 度(IC5。)測定結果表明13-烷氧代-3, 15-二氧代赤霉酸酯化合物A的IC5fl = 0. 2 ~ 47. 3 p g/mL,均具有較強的對腫瘤細胞的抑制作用。
1權利要求
1、一種具有下述結構通式(A)的化合物,名稱為13-烷氧代-3,15-二氧代赤霉酸酯,
2、如權利要求1所述的具有結構通式(A)的化合物的制備方法,其特 征是以13-鹵代-3, 15-二氧代赤霉酸酯(1)為起始原料,首先在與烷氧基相對 應的醇試劑中加入脫鹵素無機鹽試劑,然后在極性溶劑中室溫或攝氏60度至 回流溫度加熱反應,13-鹵代-3, 15-二氧代赤霉酸酯(l)的13位發生烷氧基取 代反應生成具有結構通式(A)的化合物13-垸氧代-3, 15-二氧代赤霉酸酯, 所述原料13-鹵代-3, 15-二氧代赤霉酸酯(1)的結構式如下,式中的R^CH3、 2個碳到5個碳的烷基及節基(PhCH2), X=Cl,Br。
3、 根據權利要求2所述的制備方法,其特征是所述的與烷氧基相對應的 醇試劑為甲醇、乙醇、丙醇、異丙醇、丁醇、異丁醇、戊醇、異戊醇、己醇、 環己醇、芐醇、對甲氧基芐醇或對羥基芐醇、3, 4, 5-三甲氧基節醇、3, 4-二甲氧基芐醇,用量為10 100mL溶劑/g底物。
4、 根據權利要求2所述的制備方法,其特征是所述的無機鹽試劑為碳酸 鉀、碳酸鈉、碳酸氫鈉、碳酸銀、碳酸鋰、碳酸銫、三氟醋酸銀、三氟磺酸銀、 醋酸銀或硝酸銀,用量按摩爾比為底物/無機鹽=1/1 50。
5、 根據權利要求2所述的制備方法,其特征是所述極性溶劑是相應的醇、 乙腈、丙酮或者N, N-二甲基甲酰胺。
6、 根據權利要求2所述的制備方法,其特征是制備具有結構通式(A)的13_垸氧代-3, 15-二氧代赤霉酸酯時,將13-鹵代-3, 15-二氧代赤霉酸酯(1) 在相應的醇溶劑或在乙腈或在N, N-二甲基甲酰胺溶劑中加入與烷氧基相應的 醇試劑,然后加入碳酸鉀、碳酸鈉、碳酸氫鈉、碳酸銀、碳酸鋰、碳酸銫、三 氟醋酸銀、三氟磺酸銀、醋酸銀、硝酸銀無機鹽試劑,在室溫或攝氏60度至 回流溫度加熱下反應制備目標物,反應中各化合物的用量按摩爾比為底物/ 醇/無機鹽=1/10 500/1-5。
7、權利要求1所述的具有結構通式(A)的化合物在制備治療癌癥藥物方 面的應用。
全文摘要
一種具有結構通式(A)的化合物即13-烷氧代-3,15-二氧代赤霉酸酯類物質及該化合物的制備方法,該類化合物經抗癌活性實驗證明,具有較強的體外抗腫瘤活性,R<sup>1</sup>=CH<sub>3</sub>;2-5個碳的烷基及PhCH<sub>2</sub>R<sup>2</sup>=H;Ar;ArCH<sub>2</sub>及1-5個碳的烷基式中R<sup>1</sup>為甲基、2個碳到5個碳的烷基、芐基;R<sup>2</sup>為氫、取代的芐基及1個碳到5個碳的烷基。
文檔編號C07D307/00GK101497590SQ200910094180
公開日2009年8月5日 申請日期2009年3月11日 優先權日2009年3月11日
發明者劉建平, 晨 卿, 孫竹先, 張洪彬, 張雁麗, 曾祥慧, 良 李, 陳靜波 申請人:云南大學;昆明醫學院
網友詢問留言 已有0條留言
  • 還沒有人留言評論。精彩留言會獲得點贊!
1
韩国伦理电影